Gå til innholdet
Menu

User safety

Always read carefully the package insert before use of any of our products.

Preventive safety measures

It is important that personnel carrying out the vaccination of farmed fish follow the recommended safety measures which have been designed in order to prevent or at least minimise the risk of accidental self-injection. These measures include the following:

PHARMAQ’s advice in the event of unintentional self-injection

To the vaccinator

If you have been accidentally injected with fish vaccine, seek the assistance of a doctor immediately, even if the injected amount is small.  Take the printed information from the vaccine package with you to the doctor. If pain persists for more than 12 hours after medical examination, you must consult the doctor again.

Accidental injection of fish vaccine into the human body can lead to severe pain and swelling, especially if the preparation is injected into a joint or a finger. In rare cases, the loss of an affected finger may result if treatment is not commenced immediately.

Self-injection may result in sensitisation to fish vaccine such that any subsequent self injection may produce an allergic reaction leading to anaphylactic shock. This could be life-threatening without rapid and proper treatment.

If any unfavourable and unintended effect is observed after treatment or vaccination using a veterinary medicinal product, please contact Qualified Person responsible for Pharmacovigilance (QPPV) at PHARMAQ for advice.

To the doctor

The introduction of even a small amount of a fish vaccine product into a person can result in pronounced swelling which may, result in ischaemic necrosis at the injection site or even the loss of an affected finger.

The site of injection must IMMEDIATELY be examined by a surgically competent person, and if necessary, incision and irrigation of the affected area must be performed, especially when ligaments or soft finger tissue are involved. However this type of intervention should only be undertaken if the risks associated with it outweigh those of inaction.

Repeated self-injection may reinforce the reaction thereby elevating the risk of anaphylactic shock.

Pharmacovigilance in PHARMAQ

If any unfavourable and unintended effect is observed after treatment or vaccination using a veterinary medicinal product, please contact Qualified Person responsible for Pharmacovigilance (QPPV) at PHARMAQ for advice. Read more

 

/share/mime/48/pdf.png English
(1MB)

/share/mime/48/pdf.png Norwegian
(selvstikkbrosjyre_no_2016_web.pdf, 3MB)

/share/mime/48/pdf.png Spanish
(selfinjection_brochure_2016_esp_web.pdf, 1MB)

/share/mime/48/pdf.png Vietnamese
(in_case_of_selfinjection_vietnamese.pdf, 7MB)

Norway

Head office
Production facility
PHARMAQ AS
Skogmo Industriområde
Industrivegen 50
7863 Overhalla, Norway
Tel:+47 74 28 08 00
Fax:+47 74 28 08 01

Oslo office
PHARMAQ AS
Harbitzalléen 2A, 0275 Oslo,
P.O.Box 267 Skøyen, N-0213 Oslo, Norway
Tel: +47 23 29 85 00
Fax: :+47 23 29 85 01
customer.service​@pharmaq.no

Chile

PHARMAQ AS Chile Ltda.
B